Elisa Agostinetto· @ElisaAgostinett · X·· 1 天前评分70
正文 · 原文
At #ESMO26 Proffered Paper 2️⃣ on #breastcancer
Results of the FINER trial
Ipatasertib + fulvestrant does not improve OS, neither overall nor in the AKT-mut cohort
Improvement in PFS and longer time to subsequent systemic tx or death
@OncoAlert
41 浏览 · 3 赞 · 3 转发 · 0 回复
会议摘要
LBA14按 Proffered paper 2: Breast cancer, early and advanced stage 对上
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.org来源：Elisa Agostinetto · x.com